<?xml version="1.0" encoding="UTF-8"?>
<p>ZIKV seroprevalence data were drawn from ten studies worldwide in which IgG and IgM ELISA diagnostic tests were performed, as were microsphere immunoassays in one study. The seroprevalence was the highest in Yap Island, Micronesia, at 73% (95% CI: 68–77) [
 <xref rid="pntd.0006533.ref008" ref-type="bibr">8</xref>] and in French Polynesia at 66% (95% CI: 60–71) [
 <xref rid="pntd.0006533.ref155" ref-type="bibr">155</xref>]. In French Polynesia, three studies reported seroprevalence ranging from less than 1% among blood donors to more than 50% among children, as they were conducted before and after the emergence of ZIKV, respectively (
 <xref ref-type="fig" rid="pntd.0006533.g007">Fig 7</xref>) [
 <xref rid="pntd.0006533.ref155" ref-type="bibr">155</xref>,
 <xref rid="pntd.0006533.ref161" ref-type="bibr">161</xref>]. We noted that in the Americas, ZIKV seroprevalence rates ranged between 19 and 30% [
 <xref rid="pntd.0006533.ref160" ref-type="bibr">160</xref>,
 <xref rid="pntd.0006533.ref162" ref-type="bibr">162</xref>], and in Africa, rates were less than 10% [
 <xref rid="pntd.0006533.ref156" ref-type="bibr">156</xref>,
 <xref rid="pntd.0006533.ref158" ref-type="bibr">158</xref>].
</p>
